Inhibitors of Rho kinase (ROCK) are a relatively new class of drugs with potential benefits in oncology, neurology, and fibrotic and cardiovascular diseases. ROCK inhibitors modulate many cellular functions, some of which are similar to the pleiotropic effects of statins, suggesting additive or synergistic properties. Studies to date have used compounds that inhibit both isoforms of ROCK, ROCK1 and ROCK2. This study was designed to compare gene expression profiles of atorvastatin with the newly developed ROCK2 inhibitor SLx-2119 in primary cultures of normal human endothelial cells, smooth muscle cells, and fibroblasts. Cells were treated with each compound for 24 h, after which total RNA was isolated and genomewide gene-expression profiles were obtained with Illumina arrays. Because of the known effect of statins on the actin cytoskeleton and on connective tissue growth factor, a prominent growth factor involved in tissue fibrosis, the effects of SLx-2119 and atorvastatin on the actin cytoskeleton and connective tissue growth factor mRNA were also examined in cultures of smooth muscle cells with a fibrotic phenotype, isolated from biopsies of human intestine with radiation-induced fibrosis. Although SLx-2119 and atorvastatin affected expression of genes belonging to the same biological processes, individual genes were mostly different, consistent with synergistic or additive properties. Both SLx-2119 and atorvastatin reduced connective tissue growth factor mRNA and remodeled the actin cytoskeleton in fibrosis-derived smooth muscle cells, suggesting that both compounds have antifibrotic properties. These results form the basis for further studies to assess the possible therapeutic benefit of combined treatments. 
Introduction
Rho proteins belong to a family of small guanosine 5 0triphosphates (GTP)-binding proteins involved in a wide range of cellular functions, including stress fiber formation, hypertrophy, migration, and production of cytokines and growth factors [1] . Rho proteins largely operate through their downstream mediators, Rho kinase (ROCK)1 and ROCK2. ROCK inhibitors are a relatively newly developed class of drugs that affects cellular functions by inhibiting the ROCK pathway. Despite their recent development, ROCK inhibitors have already shown substantial benefit in a wide range of diseases, including oncological disorders [2] , neurological disorders [3] , fibrotic disease [4] , and several cardiovascular disorders [5] .
The effects of ROCK inhibitors overlap to a certain extent with the pleiotropic (nonlipid lowering) effects of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). Although the main indication for statins is hyperlipidemia disorders, statins also show benefit in trauma, vascular disease, diabetes, as well as immune, inflammatory, and fibroproliferative disorders [6, 7] . Notably, there is clinical and preclinical evidence supporting the use of statins for the prevention of intestinal radiation fibrosis [8] [9] [10] .
The pleiotropic effects of statins are mostly mediated through a reduced formation of intermediates of the cholesterol biosynthesis pathway, such as farnesyl pyrophosphate and geranylgeranylpyrophosphate. These intermediates serve as substrates for isoprenylation of several peptides, including Rho proteins such as Rho, Rac, and cdc42, which is critical for their function and intracellular trafficking. As a result of altered Rho protein function, statins increase the expression and activity of endothelial nitric oxide synthase (eNOS) [11] . In addition to Rho proteins, statins also alter isoprenylation of other small proteins, such as Ras proteins. Moreover, certain pleiotropic statin effects, for example upregulation of thrombomodulin, involve Rac and cdc42, but not Rho [12] . In contrast to statins, ROCK inhibitors selectively inhibit the Rho kinase pathway. Considering these properties of statins and ROCK inhibitors, one may expect some overlap but also important differences in the effects of the two classes of compounds. Moreover, the degree of overlap between ROCK inhibitors and statins may vary depending on the cell type or the cell phenotype.
Until now, the only pharmacological tools for studying ROCK biology have been compounds that do not differentiate between ROCK1 and ROCK2. This is far from ideal as knockout [13] and siRNA [14] studies have demonstrated that the two isoforms have unique and specific effects both at the cellular level and in vivo. This study used microarrays to perform a genome-wide comparison of the effects of the small molecule ROCK2selective inhibitor, SLx-2119, with the effects of atorvastatin on gene expression in three different cell types, that is, primary cultures of human endothelial cells, smooth muscle cells (SMCs), and fibroblasts. The relevance of the findings to human disorderdisease was addressed by studying the effects of these compounds on SMC derived from clinical resection specimens of chronic intestinal radiation injury in order to model fibrosis in vitro. Our findings are consistent with the notion that the two classes of drugs may have synergistic properties and suggest that combination therapies should be explored.
Methods

Cell cultures
All cell-culture media were from Cambrex (East Rutherford, New Jersey, USA). Human microvascular endothelial cells (HMVEC; CC-2527, Cambrex) were cultured in EGM-2 MV BulletKit medium, containing endothelial cell basal medium-2, human epidermal growth factor (EGF), hydrocortisone, human basal fibroblast growth factor (hFGF-B), vascular endothelial growth factor (VEGF), recombinant insulin-like growth factor (IGF)-I, ascorbic acid, gentamicin, amphotericin-B, and 5% fetal bovine serum (FBS). Human pulmonary artery smooth muscle cells (PASMC; CC-25841, Cambrex) were cultured in SmGM-2 BulletKit medium, containing smooth muscle basal medium, human EGF, hFGF-B, insulin, gentamicin, amphotericin-B, and 5% FBS. Human dermal fibroblasts (NHDF, CC-2511, Cambrex) were cultured in FGM-2 BulletKit medium, containing fibroblast basal medium, hFGF-B, insulin, gentamicin, amphotericin-B, and 2% FBS.
SMCs were isolated from human ileal muscularis propria as previously described [15] , either normal muscularis propria (N-SMC), or from muscularis propria biopsies of patients with delayed radiation enteropathy (RE-SMC).
Intestinal tissues were collected according to the guidelines on human subject research from the French Medical Research Council. SMCs were isolated by enzymatic digestion at 378C (0.2% type II collagenase and 0.1% soybean trypsin inhibitor) and subcultured in SmGM-2.
All cell cultures were maintained at 378C in a humidified atmosphere of 5% CO 2 and 95% air.
Radiometric truncated enzyme ROCK1 and ROCK2 assays
Cell-free enzyme assays were performed to determine the selective inhibition of ROCK1 and ROCK2 by SLx-2119. Reactions were performed on nonbinding surface microplates (Corning Inc., Corning, New York, USA). Four milliunits of human ROCK1 and ROCK2 (Invitrogen, Carlsbad, California, USA) were used to phosphorylate 30 mmol/l of the synthetic ROCK peptide substrate S6 Long (sequence: KEAKEKRQEQIAKRRRLSSL-RASTSKSGGSQK), prepared at American Peptide (Sunnyvale, California, USA) with the addition of 10 mmol/l ATP (Sigma, St. Louis, Missouri, USA), containing 33 P-ATP (Perkin-Elmer, Waltham, Massachusetts, USA) in the presence of 10 mmol/l Mg 2þ , 50 mmol/l Tris, pH 7.5, 0.1 mmol/l ethyleneglycol-bis-(b-aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), and 1 mmol/l dithiothreitol (DTT) at room temperature. One unit is the amount of kinase needed to catalyze the transfer of 1 nmol phosphate/min to the peptide. The reactions were allowed to proceed for 45 min and then stopped with 3% phosphoric acid to a final concentration of 1%. The reactions were captured on phosphocellulose filtration microplates (Millipore, Billerica, Massachusetts, USA) and washed with 75 mmol/l phosphoric acid and methanol using a vacuum manifold. Phosphorylation was measured on a Perkin-Elmer MicroBeta 1450.
ROCK1 and ROCK2 western blot analysis
Western blots were used to determine whether HMVEC, NHDF, and PASMC express ROCK1 and ROCK2. All cells were collected at passage 3 and lysed on ice in 25 mmol/l Tris-HCl, pH 7.5, 150 mmol/l NaCl, 0.5% Triton X-100, 10% glycerol, 10 mmol/l NaF, and a protease inhibitor cocktail (Roche, Basel, Switzerland). Protein concentration was determined using a bicinchoninic acid (BCA) protein assay reagent (Pierce Chemical Company, Rockford, Illinois, USA). Cell lysates (35 mg) were separated on 7.5 or 12.5% SDS-PAGE polyacrylamide gels (Bio-Rad, Hercules, California, USA) and transferred to polyvinylidene fluoride (PVDF) membrane filters. Membranes were blocked in 5% nonfat milk in Tris-buffered saline (TBS) containing 0.1% Tween 20. Blots were probed with antibodies to ROCK1 (Bethyl Laboratories, Montgomery, Texas, USA), ROCK2 (H-85, Santa Cruz Biotechnology, Santa Cruz, California, USA) or actin (Santa Cruz Biotechnology) and washed well before incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies and visualization with an enhanced chemiluminescence (ECL) kit (Healthcare, Piscataway, New Jersey, USA).
Atorvastatin, mevalonate, and SLx-2119 treatment Atorvastatin (Pfizer, New York, New York, USA) was dissolved in methanol to obtain a stock solution of 10 mmol/l. Mevalonate (Sigma) was dissolved in 0.1 mol/l NaOH to obtain a stock solution of 100 mmol/l, pH 7.4. The ROCK2 inhibitor, SLx-2119, was synthesized at Surface Logix (Brighton, Massachusetts, USA) and dissolved in dimethyl sulfoxide (DMSO) to obtain a stock solution of 20 mmol/l. HMVEC, PASMC, and NHDF at passage 7, and N-SMC and RE-SMC at passage 4 were plated in 6 cm culture dishes with 3 ml culture medium, at a density of 1 Â 10 6 cells/dish. After 2 days (confluence 90%), the cells were incubated for 24 h in 3 ml culture media containing vehicle (10 ml sterile PBS), 10 mmol/l atorvastatin, a combination of 10 mmol/l atorvastatin and 500 mmol/l mevalonate, 10 mmol/l SLx-2119, or 40 mmol/l SLx-2119. Three independent experiments were performed with three culture dishes in each treatment group.
RNA isolation
Twenty-four hours after treatment of HMVEC, PASMC, and NHDF with vehicle, SLx-2119, atorvastatin, or atorvastatin combined with mevalonate, total RNA was isolated using Ultraspec RNA isolation reagent (Biotecx Laboratories, Houston, Texas, USA), according to the manufacturer's instructions. Two micrograms of RNA was kept for microarray analysis (including quality control analysis) and 2 mg was used for real-time PCR.
Twenty-four hours after treatment of N-SMC and RE-SMC with vehicle, SLx-2119, atorvastatin, or atorvastatin combined with mevalonate, total RNA was isolated as described before [15] . This RNA was used for realtime PCR. Genes were considered differentially regulated at P value less than 0.01 and a fold change of at least two.
Real-time PCR
Reversing the effects of statins by the addition of mevalonate provides an opportunity to subtract nonspecific effects of statins in vitro [17, 18] . This approach was also used in the current study as follows: genes were considered upregulated or downregulated by atorvastatin if they were upregulated or downregulated in atorvastatintreated cells versus vehicle-treated cells and when the addition of mevalonate significantly reversed the change in expression induced by atorvastatin [18] .
Genes that were upregulated or downregulated by SLx-2119 or atorvastatin were classified according to Gene Ontology biological processes [19] . Microarray data have been deposited in National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number GSE8686.
Actin staining of N-SMC and RE-SMC Phalloidin-fluorescein isothiocyanate (FITC) was used to detect stress fiber formation in N-SMC and in RE-SMC. Twenty-four hours after treatment of N-SMC and RE-SMC with vehicle, SLx-2119, atorvastatin, or atorvastatin combined with mevalonate cells were fixed in 0.5% paraformaldehyde and permeabilized in 0.1% Triton X-100. The actin cytoskeleton was visualized with phalloidin-FITC (Sigma). Staining was examined by laser scanning confocal microscopy (Zeiss LSM510).
Results
SLx-2119 selectivity
Radiometric enzyme assays confirmed that SLx-2119 selectively inhibits activity of human ROCK2 [median inhibitory concentration (IC 50 ) ¼ 105 nmol/l], while effects on human ROCK1 in this cell-free system were minimal (IC 50 ¼ 24 mmol/l, Fig. 1 ).
Microarray reproducibility and characterization of normal primary cells
Western blot analysis was used to confirm that primary cultures of HMVEC, PASMC, and NHDF express both isoforms of ROCK (Fig. 2) .
No rounded cell morphology was observed in any of the cell treatments, confirming that the drugs were not cytotoxic at the concentration used. In total, 36 microarrays were hybridized with aRNA from HMVEC, PASMC, or NHDF at 24 h after any of the treatments. One of the arrays, which was hybridized with aRNA from HMVEC treated with SLx-2119, showed a five times higher background than the other arrays. This array was omitted and the remaining 35 arrays were used for further analysis. In vehicle-treated NHDF, 10 536 genes showed a signal above background. Similarly, 10 776 genes were detected in vehicle-treated HMVEC and 9188 genes were detected in vehicle-treated PASMC. Reproducibility among biological duplicates was high, with a mean R 2 of 0.985 in HMVEC, 0.99 in NHDF, and 0.985 in PASMC.
Real-time PCR analysis of upregulated and downregulated genes
The effects of atorvastatin and SLx-2119 on selected genes were examined by real-time PCR in PASMC ( Fig. 3 ). Atorvastatin at 10 mmol/l induced an upregulation of thrombomodulin mRNA in PASMC that was reversed by mevalonate, confirming that this effect was due to an inhibition of the cholesterol biosynthesis pathway by atorvastatin. SLx-2119 did not induce an 
Microarray analysis of upregulated and downregulated genes
To select only those genes that were upregulated or downregulated by atorvastatin through inhibition of the mevalonate pathway, genes were selected only when they were upregulated or downregulated in atorvastatin-treated cells versus vehicle-treated cells and when the addition of mevalonate significantly reversed the change in expression. Table 1 shows numbers of genes that were upregulated and downregulated by atorvastatin or SLx-2119 in HMVEC, PASMC, and NHDF. Among the genes that were upregulated by atorvastatin in HMVEC were well known effectors of statins, including genes coding for eNOS, thrombomodulin, heat shock protein 27, and tissue plasminogen activator (NOS3, THBD, HSPB1, PLAT, respectively). In addition, accordance with the real-time PCR data, genes coding for Tsp-1 and CTGF (THBD and CTGF) were downregulated by atorvastatin in all three cell types. SLx-2119, on the contrary, induced a significant downregulation of Tsp-1 transcripts in HMVEC and PASMC only and induced a downregulation of CTGF transcripts, although nonsignificant, in all three cell types. Interestingly, the overlap in genes upregulated or downregulated by both drugs was relatively small in all cell types and even absent in NHDF. Moreover, the three cell types differed greatly in their response to the two drugs, as illustrated both in Table 1 and Fig. 4 . Of all upregulated or downregulated genes, 60-70% could be classified according to Gene Ontology biological process ( Table 2) . Although the two drugs exhibited little overlap in terms of the individual genes that were regulated, the genes could be classified in the same Gene Ontology biological processes. Examples are given in Table 3 , which lists all altered genes involved in cell adhesion (Gene Ontology biological process ID 7155) and coagulation (Gene Ontology biological process ID 7596) in PASMC. Analogously, in HMVEC and NHDF, both atorvastatin and SLx-2119 affected genes involved in the same biological processes although the specific genes were mostly different for the two compounds.
Phenotype-dependent effects of atorvastatin and SLx-2119
Fibrosis is not included as a separate Gene Ontology biological process. Nevertheless, atorvastatin and especially SLx-2119 were shown to alter many genes that may play a role in fibrosis. As mentioned above, atorvastatin downregulated the gene CTGF in HMVEC, PASMC, and NHDF. SLx-2119 induced a downregulation of the genes COL1A1, COL1A2, COL3A1, and COL5A2 in PASMC, an upregulation of the gene MMP1 in PASMC, a downregulation of the gene COL3A1 in NHDF, and an upregulation of the genes COL7A1, COL4A2, MMP1, MMP3, MMP14, and MMP17 in NHDF. The last column lists numbers of genes that were altered both in atorvastatintreated cells and in cells treated with SLx-2119. The overlap between atorvastatin and SLx-2119 was small and even absent in NHDF. HMVEC, human microvascular endothelial cells; NHDF, human dermal fibroblasts; PASMC, pulmonary artery smooth muscle cells. The last column lists numbers of genes that were found altered both after atorvastatin treatment and after SLx-2119 treatment. Note that some genes belong to more than one biological process and are therefore counted multiple times.
To address the possibility of phenotype-dependent effects of atorvastatin and SLx-2119, SMC were isolated from biopsies of normal human intestine (N-SMC) and from human intestine with radiation-induced fibrosis (RE-SMC). Because CTGF overexpression is known to be associated with fibrotic diseases, the effects of atorvastatin and SLx-2119 on CTGF mRNA were examined by real-time PCR in N-SMC and RE-SMC ( Fig. 5a ). Atorvastatin and SLx-2119 did not significantly alter CTGF mRNA level in N-SMC. In contrast, both drugs reduced CTGF mRNA level in RE-SMC in which CTGF base-line expression is elevated. Inhibition of CTGF mRNA by SLx-2119 occurred at 1 mmol/l with no further inhibition with increasing concentrations. Atorvastatin inhibitory action on CTGF was reversed by mevalonate, confirming that this effect was due to an inhibition of the mevalonate pathway. Modulation of CTGF induced by compounds that interfere in the Rho/ ROCK pathway (such as statins and the ROCK inhibitor Y-27632) is thought to be associated with alteration of the actin cytoskeleton, which was also suggested by the stress fiber network modifications in the current study. Atorvastatin and SLx-2119 reduced and remodeled Factin staining, both at a concentration of 10 mmol/l, in RE-SMC and N-SMC (Fig. 5b) . The stress fibers became sparse in the central cell body, but the cytoplasmic processes remained. Mevalonate reversed the effects of atorvastatin.
Discussion
In this study, microarrays were used to perform a genome-wide comparison of the effects of ROCK2-selective inhibitor SLx-2119 with the effects of atorvastatin in primary cultures of human endothelial cells, SMCs, and fibroblasts. The study showed that although SLx-2119 and atorvastatin induced altered expression of genes belonging to the same biological processes, individual genes affected by these drugs were mostly different. These results suggest that there may be synergistic effects between statins and ROCK2 inhibitors, and that a possible therapeutic benefit may be achieved by combining the two classes of drugs.
When interpreting effects of drugs on cells in culture, it is important to consider to what extent in-vitro concentrations are attainable in vivo. In our laboratory, the investigation of pleiotropic effects of statins such as thrombomodulin upregulation [20] and CTGF downregulation [21] are a major focus. Hence, we have shown previously that atorvastatin at a concentration of 10 mmol/l consistently upregulates thrombomodulin gene and protein expression in cell cultures [20] . Moreover, administration in vivo of another HMG-CoA reductase inhibitor to mice at a nontoxic dose also caused increased thrombomodulin gene expression levels in lung tissue (unpublished observation, 2008). In humans, peak plasma concentrations after oral administration of clinically relevant doses of atorvastatin, administered for its lipid-lowering effects (10-40 mg), are 0.5-10 nmol/l [22, 23] . Peripheral tissue concentrations and intracellular concentrations of atorvastatin have, to our knowledge, not been described. In the current study, SLx-2119 downregulated Tsp-1 and CTGF transcripts but only at a concentration of 40 mmol/l. Hence, the in-vitro microarray studies reported here were performed with concentrations of atorvastatin and SLx-2119 of 10 and 40 mmol/l, respectively. These concentrations are likely higher than tissue and/or intracellular concentrations that can be achieved in vivo. On the contrary, cells in vivo are generally exposed to a drug for much longer periods of time than cells in culture. Because of these and other considerations, studies in animals and/or humans will ultimately be required to examine whether the synergistic effects of SLx-2119 and atorvastatin suggested by the present study apply to the in-vivo situation.
In radiometric assays, the IC 50 value of SLx-2119 for inhibition of ROCK1 was 24 mmol/l. Partial inhibition of ROCK1 may thus be expected at the concentration of SLx-2119 used in the microarray studies (40 mmol/l). However, SLx-2119 is an ATP-competitive inhibitor of ROCK. Therefore, in cell-based assays in which intracellular levels of ATP are 10-100-fold higher than the concentration of ATP used in the radiometric assay, the potency of SLx-2119 for ROCK2 may be expected to be in the 1-10 mmol/l range and for ROCK1 much greater Gene expression after ROCK inhibition or statin Boerma et al. 715 Table 3 Genes involved in cell adhesion (Gene Ontology biological process ID 7155) and blood coagulation (Gene Ontology biological process ID 7596) that were altered by atorvastatin or SLx-2119 in pulmonary artery smooth muscle cells
Gene symbol Accession number
Upregulated or downregulated Atorvastatin SLx-2119
than 200 mmol/l. Hence, at the concentrations used in this study, SLx-2119 selectively inhibits ROCK2.
An example of how ROCK2 inhibitors and statins may be complimentary to each other can be found in the effects of SLx-2119 and atorvastatin on genes involved in blood coagulation. Statins have known antifibrinolytic effects on vascular cells [24] . Moreover, the current and former studies have shown that statins upregulate expression and function of thrombomodulin [12, 18, 20] . Thrombomodulin is located on the luminal surface of endothelial cells in most normal blood vessels, in which it forms a complex with thrombin. When complexed to thrombomodulin, thrombin no longer cleaves fibrinogen to form fibrin and no longer activates cellular thrombin receptors, but instead activates protein C. Activated protein C counteracts the procoagulant, inflammatory, and fibroproliferative effects of thrombin. Recent studies have demonstrated that increased levels of thrombomodulin attenuate inflammatory responses in a variety of settings, including endotoxin-induced tissue damage and atherosclerosis [25, 26] . Statins may be therapeutically beneficial in various disorders by upregulating expression of thrombomodulin. Interestingly, SLx-2119 did not affect expression of thrombomodulin in any of the investigated cell types. However, this ROCK2 inhibitor could possibly enhance the therapeutic benefit of statins, by affecting the expression of other antifibroproliferative or anticoagulant factors that are not affected by statins, such as urokinase plasminogen activator (PLAU) and urokinase plasminogen activator receptor (PLAUR). SLx-2119 does not alter prothrombin time (J.L. Ellis, unpublished observation).
Statins are also well known to downregulate genes coding for Tsp-1 and CTGF [18, [26] [27] [28] . These factors are important mediators in the transforming growth factor (TGF) pathway, as Tsp-1 is an activator of TGF and CTGF is one of the main downstream mediators of TGF. The TGF pathway plays a central role in many conditions that lead to fibrosis [29] [30] [31] . Current microarray data show that SLx-2119 alters the expression of a plethora of genes that may be related to fibrosis and tissue remodeling, including genes coding for several collagen types and matrix metalloproteinases (MMPs), in PASMC and NHDF. These genes were not altered by atorvastatin, again suggesting that the two classes of drugs may have synergistic effects. By altering CTGF and other fibroproliferative mediators, both statins and ROCK inhibitors have indeed been shown to alter the fibrotic phenotype of SMC and fibroblasts [15, 21, 32] . In this study, we compared the effects of SLx-2119 and atorvastatin on SMC isolated from radiation enteropathy biopsies. As shown previously [15, 21] , these cells exhibit a profibrogenic phenotype characterized by increased formation of actin stress fibers and an increased expression of CTGF when compared with SMC isolated from normal intestine. Both atorvastatin and SLx-2119 reduced stress fiber formation and CTGF expression specifically in the RE-SMC. Similar results were found in endothelial cells in previous studies, in which ROCK inhibitors and statins reduced stress fiber formation and endothelial permeability in response to irradiation or thrombin [33, 34] .
Interestingly, N-SMC from intestine and normal PASMC differed in their response with regard to CTGF. Although this difference may be explained by differences in culture conditions and differences in origin between the two SMC types, different responses of different cells may also be caused by the many targets and diverse effects of Rho proteins. This was also found in a previous study, in which microarrays were used to investigate the effects of ROCK inhibitor Y-27632 on three different human fibroblast phenotypes [35] . Similar to the current study, the ROCK inhibitor affected many genes involved in cellcycle regulation and cytokinesis. Furthermore, it was concluded that the ROCK inhibitor had phenotypespecific effects on these cells. A similar difference was found on effects of Rho/ROCK inhibition on normal and fibrotic phenotypes of intestinal SMC in the current study.
As reported before for statins [36] , the different cell types in the current study differed greatly in their gene expression response to atorvastatin or SLx-2119, including the total number of genes affected. For example, atorvastatin had little effect on gene expression in fibroblasts, whereas SLx-2119 had a major effect. This predominant response of SLx-2119 on fibroblasts likely parallels the role of ROCK2 in the fibrotic response [10] and the potential for ROCK2 inhibitors to be beneficial in fibrotic disease.
Conclusion
The results of the current gene expression profiling study show that atorvastatin and the ROCK2 inhibitor SLx-2119 exhibit little overlap, but instead are mainly complimentary in their effects on gene expression in several primary human cell cultures. These data are consistent with a potential synergistic effect between statins and ROCK inhibitors. It should also be noted that the ROCK pathway affects the function of several target proteins by post-translation modification. Hence, more in-vitro and in-vivo studies are needed to further explore the possible therapeutic benefit of treatments in which ROCK inhibitors and statins are combined.
